South China Morning Post reports Tencent is scouring the world for partners in revolutionizing medicine. Tencent seeks to leverage its advantage in AI to improve Parkinson’s disease treatment. By teaming with British-based Medopad (founded in 2011), the partners seek to develop a remote monitoring system for patients with severe movement disorders. There ultimate goal is to support patient-centric clinical care—by enabling physicians to set drug doses and modify care without patients coming into the hospital. Medopad has received investment from German pharmaceutical company Bayer and reports they have signed $131 million worth of deals including Chinese-based Tencent.